康德萊醫械(1501.HK)首日上市高開29.81%
格隆匯11月8日丨中國領先的心內介入器械製造商康德萊醫械(1501.HK)首日上市高開29.81%,開報27港元,盤前成交2.09億港元,最新總市值43.2億港元。該股IPO價格為20.8港元,認購倍數267.97倍。公司產品主要用於心血管介入手術、特別是PCI手術。而在中國,PCI手術數量由2014年的50萬宗增至2018年的90萬宗,按複合年增長率16.3%上升。預期有關數量將會進一步呈指數增長,並於2023年達180萬宗,因此公司產品有望持續放量。招股書顯示,公司16-18年總收益分別為1.06億、1.38億及2.03億元人民幣,年複合增長率為38.1%,資產擴張較快。而這三年中公司的淨利潤率則在逐年下降,分別為31.9%、29.6%和28.7%,三費費率亦在逐步提升。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.